<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730973</url>
  </required_header>
  <id_info>
    <org_study_id>2020-005663-31</org_study_id>
    <nct_id>NCT04730973</nct_id>
  </id_info>
  <brief_title>CARotid plaqUe StabilizatiOn and Regression With Evolocumab.</brief_title>
  <acronym>CARUSO</acronym>
  <official_title>CARotid plaqUe StabilizatiOn and Regression With Evolocumab: the CARUSO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Ordine Mauriziano di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Ordine Mauriziano di Torino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CARUSO trial aims at investigating the efficacy of evolocumab in promoting carotid plaque&#xD;
      morphological stabilization and regression as compared to traditional lipid lowering therapy&#xD;
      (LLT). Primary end-point of the study is the superiority of evolocumab on top of ongoing LLT&#xD;
      versus ongoing LLT in carotid plaque morphological stabilization and regression at 6 and 12&#xD;
      months, respectively. Secondary end-points are: LDL-Cholesterol (LDL-C) absolute and&#xD;
      percentage changes in the two groups at 12 month follow-up, and adverse cerebrovascular and&#xD;
      cardiac events at 12 and 24 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optimal lipid-lowering therapy (LLT) is a mainstay for the therapeutic management of&#xD;
      atherosclerotic vascular disease. Cardiac and cerebrovascular adverse events and progression&#xD;
      of atherosclerosis are, indeed, reduced in proportion to the achieved LDL cholesterol (LDL-C)&#xD;
      levels.In addition, regression of atherosclerotic plaques with optimal LLT has been observed.&#xD;
      However, optimal LLT with statin and ezetimibe, might be limited by the onset of adverse&#xD;
      effects (i.e. disabling myalgias, diarrhea) with are usually dose -dependent, and the maximum&#xD;
      tolerated statin dose might be insufficient to reach the recommended LDL-C goals. The advent&#xD;
      of proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) has allowed the&#xD;
      achievement of very low LDL-C levels, and the fulfillment of the recommended LDL-C targets.&#xD;
      However, while the experience with PCSK9i in patients with coronary artery disease has been&#xD;
      wide, and coronary plaque regression has been documented, little is known regarding carotid&#xD;
      plaque regression following therapy with PCSK9i. Only a few case reports have been published,&#xD;
      and no observational study has been carried out so far. Furthermore, morphological carotid&#xD;
      plaque stabilization has a prognostic role, and the possibility of its early achievement with&#xD;
      PCSK9i may be relevant, especially in the context of percutaneous or surgical carotid&#xD;
      interventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Single blinded study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Morphological carotid plaque stabilization</measure>
    <time_frame>Six months</time_frame>
    <description>Morphological stabilization of the carotid plaque evaluated with Carotid duplex ultra-sonography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotid plaque regression</measure>
    <time_frame>12 months</time_frame>
    <description>Carotid plaque regression evaluated with Carotid duplex ultra-sonography and defined as reduction of the entity of the stenosis and/or peak systolic velocity by at least 5%, as compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of LDL-C</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute changes of LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cerebrovascular events</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>All-cause mortality, cardiovascular mortality, stroke, myocardial infarction, any coronary or peripheral revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Carotid Artery Disease</condition>
  <arm_group>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous evolocumab 140 mg will be administered every 2 weeks on top of optimal lipid-lowering therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No further treatment besides optimal lipid-lowering therapy will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy</description>
    <arm_group_label>Evolocumab</arm_group_label>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lipid-lowering therapy (LLT)</intervention_name>
    <description>lipid-lowering therapy (LLT)</description>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        asymptomatic patients with uni- or bilateral carotid artery stenosis ≥50% and LDL-C values&#xD;
        ≥100 mg/dL despite ongoing lipid lowering therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;18 or ≥81 years old&#xD;
&#xD;
          -  known intolerance to evolocumab&#xD;
&#xD;
          -  ongoing or previous treatment with PCSK9i&#xD;
&#xD;
          -  prior stroke or transient ischemic attack&#xD;
&#xD;
          -  total carotid occlusion&#xD;
&#xD;
          -  major active infection or major hematologic, renal, hepatic, or endocrine dysfunction&#xD;
&#xD;
          -  malignancy with life expectancy below 24 months&#xD;
&#xD;
          -  failure to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiziana Claudia Aranzulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ordine Mauriziano di Torino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiziana Claudia Aranzulla, MD</last_name>
    <phone>+390115085038</phone>
    <email>taranzulla@mauriziano.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ordine Mauriziano di Torino</name>
      <address>
        <city>Torino</city>
        <state>Piedmont</state>
        <zip>10134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiziana Claudia Aranzulla, MD</last_name>
      <phone>+393383145483</phone>
      <email>aranzulla.tiziana@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Irene Borsotti</last_name>
      <phone>+390115082222</phone>
      <email>lborsotti@mauriziano.it</email>
    </contact_backup>
    <investigator>
      <last_name>Tiziana Claudia Aranzulla, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvatore Piazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Ricotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Musumeci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Gaggiano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Aranzulla TC, Piazza S, Ricotti A, Musumeci G, Gaggiano A. CARotid plaqUe StabilizatiOn and regression with evolocumab: Rationale and design of the CARUSO study. Catheter Cardiovasc Interv. 2021 Jul 1;98(1):E115-E121. doi: 10.1002/ccd.29743. Epub 2021 Apr 24.</citation>
    <PMID>33893754</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 24, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Ordine Mauriziano di Torino</investigator_affiliation>
    <investigator_full_name>Tiziana Claudia Aranzulla</investigator_full_name>
    <investigator_title>MD, MSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

